Resolvyx Pharmaceuticals announced promising results for patients that suffer from dry eye syndrome during Phase 2 of a new class of anti-inflammatory medications. RX-10045, as it is now called, is a resolvin compound administered as an eye drop. In a 28 day study patients reported improved symptoms and the doctors reported a statistically significant improvement in the patients dry eyes. The entire press release is available on the Resolvyx Pharmaceuticals website. This is great news for patients that suffer from dry eyes. This is one of many medications on the horizon for the pharmaceutical treatment of dry eyes.
Dr. Driscoll’s book An Eye Doctor Answers is now available on Amazon.com